No Data
No Data
Haohai Biotec (06826.HK) spent 2.8591 million yuan on July 23 to repurchase 0.047 million A shares.
On July 23, Gelunhui reported that Haohai Biotech (06826.HK) announced the repurchase of 0.047 million A-shares at a cost of 2.8591 million RMB on July 23, 2024, with a repurchase price of 60.09-61.54 RMB per share.
HKEX Stock Market Live | Ec Healthcare (02138) fell more than 6%, leading the decline in the medical beauty concept. The demand for medical beauty is temporarily under pressure, and the growth in the second quarter is slightly under pressure.
Aesthetic medicine stocks collectively declined, as of press time, ec healthcare (02138) fell by 5.45%, at HKD 1.04; shanghai haohai biological technology (06826) fell by 4.56%, at HKD 30.35; sisram med (01696) fell by 3.69%, at HKD 3.13.
haohai biotec (06826.HK) repurchased 0.039 million shares on July 22 for a total of 2.4441 million yuan.
On July 22, Gelunhui announced that Haohai Biotech (06826.HK) will spend 2.4441 million yuan to repurchase 0.039 million shares on July 22, 2024, with a repurchase price of 62.27-62.9 yuan per share.
Aesthetic medicine stocks are under pressure, and Sisram Medical (01696) fell by 4.02%. Daiwa expects macro and policy factors to suppress the growth of cosmetic medicine companies in the second half of the year.
Aesthetic medicine concept stocks are under pressure, with Sisram Med (01696) falling 4.02%, Haohai Biotech (06826) falling 2.18%, Perfect Medical (01830) falling 1.92%, and Rui'er Group (06639) falling 1.39%. On the news side, Morgan Stanley's report pointed out that under the sustained anti-corruption factor in the mainland, the market is expected to have weak second-quarter performance of medical technology companies. Investors are concerned about the timing and scale of the upcoming central government's fiscal stimulus plan, which sets expectations for medical technology stocks for the second half of this year and next year. Meanwhile, macro and policy aspects
Haohai biotec (06826.HK) repurchased 0.016 million A-shares on July 19th for a total of 0.9836 million yuan.
On July 19th, Geelonghui reported that Haohai biotec (06826.HK) announced that it will spend 0.9836 million yuan to repurchase 0.016 million shares on July 19, 2024, at a repurchase price of 60.58-61.7 yuan per share.
On July 18th, haohai biotec (06826.HK) spent 4.5041 million yuan to repurchase 0.074 million shares.
On July 18th, Gelonhui announced that Haohai Biotec (06826.HK) will buy back 0.074 million shares for a total of 4.5041 million yuan on July 18, 2024. The repurchase price is between 60.67-61 yuan per share.
No Data